vTv Therapeutics (VTVT) Cash & Equivalents (2014 - 2026)

vTv Therapeutics (VTVT) has 13 years of Cash & Equivalents data on file, last reported at $98.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 215.39% year-over-year to $98.1 million; the trailing twelve-month figure through Mar 2026 stood at $98.1 million (up 215.39% YoY), and the FY2025 full-year result was $88.9 million, up 142.02% from the prior year.
• Cash & Equivalents climbed to $98.1 million in Q1 2026, from $88.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $98.5 million in Q3 2025 to a low of $8.2 million in Q3 2023.
• A 5-year average of $36.8 million and a median of $25.9 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 46.41% in 2023 and surged 407.32% in 2024, its largest moves.
• Tracing VTVT's Cash & Equivalents over 5 years: stood at $12.1 million in 2022, then decreased by 22.1% to $9.4 million in 2023, then soared by 289.01% to $36.7 million in 2024, then soared by 142.02% to $88.9 million in 2025, then grew by 10.29% to $98.1 million in 2026.
• Business Quant data shows VTVT's Cash & Equivalents at $98.1 million in Q1 2026, $88.9 million in Q4 2025, and $98.5 million in Q3 2025.